SynthesisBMC cardiovascular disorders2025
Effect of carperitide on clinical outcomes among patients with acute heart failure: a meta-analysis of randomized and propensity‑matched studies.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarperitide, which is an α-human A-type natriuretic peptide, is used intravenously for the treatment of acute heart failure (AHF) primarily in Japan. However, its clinical effectiveness has not been established. The aim of this meta-analysis was to assess the effect of carperitide on the clinical outcomes of patients with AHF.
methodsWe searched the MEDLINE, ICHUSHI, Cochrane Library and Web of Science databases using a defined search strategy to identify eligible randomized controlled trials (RCTs) and propensity score matching (PSM) studies. The primary outcome was in-hospital mortality. The secondary outcomes were long-term mortality, HF rehospitalization, length of hospital stay and hypotension. Pooled odds ratios (ORs)/mean differences and 95% confidence intervals (CIs) were calculated by using the random effects model.
resultsA total of nine studies were evaluated in the meta-analysis, including four RCTs and five PSM studies. A meta-analysis of RCTs and PSM studies revealed that the in-hospital mortality rate was higher in the carperitide group than in the noncarperitide group (OR 1.38; 95% CI 1.07-1.78; I
conclusionsThis meta-analysis suggested that carperitide therapy may not be superior to noncarperitide therapy in terms of reducing in-hospital mortality rates or improving long-term outcomes in patients with AHF.
trial registrationThe review protocol was registered in PROSPERO (ID: CRD420251071777).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.